Juan Gómez Rivas: External validation of nomograms for predicting LNI in prostate cancer
Juan Gómez Rivas, Associate Professor at The Complutense University of Madrid, shared an article he and his colleagues authored on X:
“External validation of nomograms for predicting lymph node invasion (LNI) in prostate cancer patients with negative PSMA PET-CT. What did we find? The Briganti 2023 nomogram is the most accurate!
Why does it matter?
Extended pelvic lymph node dissection (ePLND) is the gold standard for staging but comes with risks. With PSMA PET-CT revolutionizing imaging, we need better predictive tools to avoid unnecessary procedures.
Key Findings:
• Among 282 patients, 13% had LNI despite negative PSMA PET-CT.
• The Briganti 2023 nomogram outperformed others (C-index: 77% vs. MSKCC 64%, Briganti 2017 69%, Amsterdam-Brisbane-Sydney 64%).
• Using a 5% risk cutoff would spare 47% of ePLND procedures while missing only 3.8% of LNI cases!
Clinical Impact:
• Improves decision-making: More precise risk stratification means fewer unnecessary surgeries.
• Saves patients from complications: ePLND has side effects; avoiding it when possible is crucial.
• Guides personalized treatment: Selecting the right patients for ePLND enhances care quality.
Takeaway: The Briganti 2023 nomogram should be the go-to tool for predicting LNI in prostate cancer patients with negative PSMA PET-CT!
Read the full study here.”
Authors: Giorgio Gandaglia et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023